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Abstract 
Background 
When sentinel node dissection reveals breast cancer metastasis, completion 
axillary lymph node dissection is ideally performed during the same operation. 
Intraoperative histologic techniques have low and variable sensitivity. A new 
intraoperative molecular assay (GeneSearch BLN Assay; Veridex, LLC, Warren, 
NJ) was evaluated to determine its efficiency in identifying significant sentinel 
lymph node metastases (>.2 mm).  
Methods 
Positive or negative BLN Assay results generated from fresh 2-mm node slabs 
were compared with results from conventional histologic evaluation of adjacent 
fixed tissue slabs.  
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Results 
In a prospective study of 416 patients at 11 clinical sites, the assay detected 98% 
of metastases >2 mm and 88% of metastasis greater >.2 mm, results superior to 
frozen section. Micrometastases were less frequently detected (57%) and assay 
positive results in nodes found negative by histology were rare (4%).  
Conclusions 
The BLN Assay is properly calibrated for use as a stand alone intraoperative 
molecular test.  
Keywords 
Breast cancer, Molecular, Gene, Diagnostic, Auxiliary 
 
 
________________________ 
For breast cancer patients, the status of the axillary sentinel lymph node(s) (SLN) 
provides important staging information and usually determines whether formal 
axillary lymph node dissection will be performed. If axillary node dissection is 
needed, it is ideally performed immediately after SLN dissection during the same 
operation. Current, widely practiced, intraoperative methods for detecting SLN 
metastases include frozen section and touch preparation (imprint cytology). Both 
of these approaches have limited sensitivity with wide performance variability 
compared with postoperative permanent section histology. When compared with 
final permanent pathology results, the reported sensitivity of frozen section SLN 
analysis varies from 58% to 87% [1]. Touch preparation has similar limitations in 
sensitivity [2]. A positive intraoperative SLN finding spares the patient a later 
return to surgery for completion axillary dissection. However, substantial false-
negative findings with current histologic intraoperative methods cause patients 
and their families significant distress when they are told later that the test was 
incorrect. Not only must the patient and her family go through a second 
operation, but they also have to cope with the news that the prognosis is worse 
and the required treatment more extensive than they had believed. In addition, 
the second surgery after a false-negative frozen section incurs additional costs 
and potential additional anesthetic and operative morbidity.  
Accurate intraoperative molecular analysis of all or part of the SLN offers the 
potential to significantly reduce false-negative findings that necessarily occur with 
the limited tissue sampling of conventional histologic methods [3], [4], [5], [6] and 
[7]. Although a molecular assay can overcome the errors resulting from limited 
tissue sampling associated with traditional histologic evaluation, several new 
challenges arise. First, unless calibrated appropriately, molecular assays may 
detect clinically insignificant amounts of metastatic cellular material. Presently, 
nodal breast cancer metastatic deposits <.2 mm are classified as node negative 
_______________________ 
Authors’ version prior to publication.  The published version is available at 
http://dx.doi.org/10.1016/j.amjsurg.2007.07.008, copyright © 2007 by Excerpta Medica Inc. 
(N-0) [8], with minimal or unknown clinical importance. A molecular breast SLN 
assay must be calibrated to routinely indicate a positive result only with quantities 
of disease ≥.2 mm to spare patients from axillary dissections or adjuvant 
chemotherapy, which would be considered unwarranted by current standards. 
Second, the molecular assay must be validated in an independent dataset to 
confirm proper calibration.  
The validation of a molecular SLN assay with accuracy superior to conventional 
sampling-based histology presents an even more challenging problem. Because 
of the likelihood that an accurate molecular assay will be more thorough than 
conventional histology, the assay will likely detect disease missed by the 
reference histologic test to which it is compared. Traditional test validation 
methodology would misleadingly term such a finding “false-positive.” Therefore, a 
modified approach is needed.  
We evaluated a novel, intraoperative reverse transcriptase-polymerase chain 
reaction assay for SLN breast cancer metastasis (GeneSearch BLN Assay; 
Veridex, LLC, Warren, NJ) in a prospective, multisite trial. The molecular test was 
calibrated in vitro so that positive findings were only associated with significant 
levels of the targeted messenger RNA transcripts [9]. We have presented a 
comprehensive, classic sensitivity and specificity evaluation of this new test 
elsewhere [10]. In the current analysis, we hypothesized that agreement between 
the molecular test on one part of the SLN and conventional pathology from 
another part (alternating slices) would be greatest when metastatic involvement 
was most extensive, as would be expected with histologic evaluation of 
alternating tissue sections of the same node. We also examined assay 
performance related to breast tumor type and stage and compared assay 
performance with the performance of current intraoperative tests. In particular, 
we investigated if the assay could be particularly beneficial for difficult-to-detect 
metastases, such as those seen in stage I cancer or lobular cancer. Lobular 
metastases are particularly challenging for conventional, sampling-based 
histologic methods because they are often distributed as diminutive clusters or 
single cells. There is growing consensus that such metastatic deposits should be 
counted as node positive, even when none is >.2 mm, when a substantial 
amount of the node is so involved [11].  
Methods 
The calibration and validation of the molecular BLN Assay required 2 separate 
trials: (1) a beta (cutoff) trial of 304 patients to establish a threshold between 
insignificant and significant levels (corresponding with histologic metastatic 
deposits >.2 mm) of the markers mammaglobin and cytokeratin 19 (CK19) and 
(2) a pivotal (validation) trial of 416 patients for independent performance 
verification compared with permanent-section hematoxylin and eosin and 
immunohistochemical evaluation. Both trials were completed between July 2004 
and December 2005 (Pre-IDE I040002). Patients at least 18 years of age with a 
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diagnosis of invasive adenocarcinoma of the breast and scheduled for a SLN 
dissection were eligible for the calibration or validation study. Patients were 
excluded if they were participating in other research studies that would prevent 
their full study participation, if they had a prior axillary surgery on the same body 
side as the scheduled SLN dissection, if proper informed consent signature was 
not obtained, or if they did not meet inclusion criteria listed earlier. All patients in 
the final data analysis had written informed consent, and the study protocols 
were reviewed and approved by the appropriate ethics review board at each site.  
Twelve clinical sites in the United States were selected based on clinical trial 
performance history and previous research experience with SLN studies through 
the American College of Surgeon’s Oncology Group or The National Surgical 
Adjuvant Bowel and Breast Project. Site technicians were trained and qualified 
with the BLN Assay technology.  
Node processing and comparison of BLN Assay findings with conventional 
histology 
SLNs were identified intraoperatively and dissected according to the standard 
procedures of each site. Nodes were transported to the pathology testing area 
within 15 minutes. All nodes designated as sentinel nodes (including “grossly 
positive” nodes) were analyzed, except at the site pathologist’s discretion (ie, 
node too small for adequate histological assessment for patient care if shared for 
molecular assay) or because of protocol deviation. Each node was sectioned 
along the short axis into an even number of slabs (1.5–3.0 mm thick). Alternate 
slabs were prepared for histologic evaluation or the BLN Assay. Histologic 
evaluation of each lymph node complied with or exceeded current College of 
American Pathologists’ recommendations. The BLN Assay procedure using 
reverse-transcriptase polymerase chain reaction includes liquefaction of the 
selected tissue, allowing comprehensive analysis of all cellular material in the 
tissue sample, thus eliminating sampling error. Unfortunately, the same tissue 
slab cannot be examined by both the BLN assay, which uses fresh tissue, and 
conventional histology, which uses formalin-fixed tissue. This makes direct 
comparison between the 2 methods on the exact same tissue impossible. 
Comparison of findings from adjacent tissue slabs is required. Perfect 
concordance between adjacent tissues cannot be expected because small 
metastases may be singular or spaced several millimeters apart. However, if 
both tests accurately detect metastatic disease, increasing the number or size of 
the metastatic cellular colonies will be associated with an increasing 
concordance of findings in adjacent tissue slabs.  
Site slides and histologic intraoperative tests 
The tissue slabs reserved for histologic analysis were processed for permanent-
section hematoxylin and eosin, according to the standard operating procedures 
of each site (site slides). The site also analyzed intraoperative frozen section or 
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touch preparation slides taken from these same slabs according to their standard 
methods. Patient management was based solely on histologic analysis. Site 
personnel and patients were blinded to results from the BLN Assay.  
Central slides 
Additional histologic sections (central slides), adjacent to but separate from the 
sections prepared as Site Slides were taken, processed for permanent-section 
hematoxylin and eosin, and sent to a central pathology site for evaluation. Tissue 
was sectioned for central slides according to the study protocol; three 4- to 6-µm 
thick sections were collected at 3 levels, approximately 150 µm (.15 mm) apart. 
(Note: this would detect a .2-mm metastasis in a 1.5-mm slab in one third of 
cases or in a 3.0-mm slab in one sixth of cases, exceeding current College of 
American Pathologists’ recommendations). When no metastasis was observable 
with hematoxylin and eosin staining, adjacent sections were also stained for 
immunohistochemical analysis, either on-site or by an outside laboratory (Albany 
Medical College, Department of Pathology, Albany, NY) and evaluated by the 
site pathologist or sent to the central laboratory for evaluation.  
Histologic evaluation 
Hematoxylin and eosin site slides and any site immunohistochemistry slides were 
examined by the site pathologist for evidence of metastases. All positive 
histologic findings (hematoxylin and eosin or immunohistochemical) on site slides 
were reviewed by central pathologists.  
Each hematoxylin and eosin central slide was independently evaluated at the 
central pathology laboratory by 2 pathologists and a third pathologist in cases of 
disagreement. Only nodes with central review slide hematoxylin and eosin results 
were included in the study. A patient was considered positive if 2 independent 
pathologists evaluated the same histologic sections (either hematoxylin and 
eosin or immunohistochemistry slides) as containing metastasis >.2 mm. Central 
versus site slide results analysis permitted estimation of the amplitude of 
sampling error associated with conventional histologic evaluation (see Results). 
The overall histology result (OHR) was determined for each patient. When either 
the final central slides and/or final site slides (confirmed by central review) result 
was positive, the OHR for the node was designated positive. If either the site 
slide and/or any immunohistochemical results were not available, the central 
slide result alone was used as the OHR for the node.  
GeneSearch BLN Assay results 
All GeneSearch BLN Assay results were provided to Veridex for analysis (and 
blinded to site personnel). To provide a positive or negative assay sample result, 
the quantitative expression data were applied against specific mammaglobin and 
CK19 cutoff values based on data from the calibration (cutoff) study. The cutoff 
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values were selected to correspond to histologically identified metastases >.2 
mm in adjacent tissue slabs in 95% of cases. The cutoff values determined in the 
cutoff study (n = 304 patients) were then applied to the validation data set 
consisting of results from 416 independent patients. The assay result for a 
patient was considered positive if any node from the patient tested positive. If all 
nodes from a patient tested negative, then the assay result for the patient was 
considered negative. If the sample result from any node from a patient was 
invalid and all other node sample results were also invalid or negative, then the 
assay result for that patient was considered invalid.  
Analysis 
The primary endpoint was the overall agreement between the BLN Assay and 
the OHR for a given patient indexed to the size of metastatic deposits detected 
by histology and related to lobular versus other histology in the primary tumor. 
Secondary endpoints included (1) agreement of the BLN Assay with the OHR 
versus that of intraoperative frozen section and touch preparation and (2) a 
comparison of site slide versus central slide findings to provide a sampling error 
estimate for histological analysis. Eligible patients with invalid BLN Assay results 
were considered assay negative for performance calculations and were included 
in the analyses because, in clinical use, invalid results would not provide 
conclusive evidence of metastases and would provide the surgeon with no 
information on which to base clinical decisions. Invalid results can arise from 
inappropriate sampling (eg, all fatty tissue or no nodal tissue), operator error, or 
equipment malfunction. Bayesian statistical study design and analysis were 
performed and provided by Berry Consultants (Don Berry, Ph.D, and Scott Berry, 
Ph.D., Houston, TX). Statistical analyses, SAS programming, and validation were 
performed by Veridex.  
Results 
Experienced technicians performed the assay on 1 to 3 nodes in about 30 to 35 
minutes compared with about 35 to 55 minutes for those with less practice. 
Assay performance was very similar in the validation and cutoff studies. Data are 
reported here for the validation study, except when the sample sizes are small; 
then the data are shown for both studies separately and combined. All analyses 
were performed on a “per-patient” basis. The intraoperative BLN Assay detected 
disease in 98% (95% confidence interval, 93%–100%) of cases when 
histologically confirmed metastases >2 mm were found in adjacent tissue slabs 
(n = 94). The assay was positive in 57% (95% confidence interval, 35%–77%) of 
patients when micrometastatic disease .2 to 2 mm was detected in the adjacent 
slabs (n = 23). Overall, the assay reported metastasis 88% of the time when 
metastatic disease ≥.2 mm was detected histologically in adjacent tissue slabs. 
When metastases <.2 mm were found on histologic sampling of the adjacent 
tissue slabs (small clusters or isolated tumor cells), the assay was positive in 5 of 
20 patients. The assay was positive in 12 of 275 (4%) patients with no 
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histologically detected cancer in adjacent tissue slabs. Table 1 shows the 
summary of BLN Assay results and OHR agreement.  
Assay performance was similar across different stages of disease and across 
various tumor types (Table 2). The assay reported disease in approximately 80% 
of patients when lobular metastases (particularly difficult to identify by histology 
[4]) were present in adjacent tissue slabs. Table 3 shows the assay performance 
in lobular cancer patients in the validation study, cutoff study, and both studies 
combined when compared with OHR (permanent section histology).  
Table 4 shows in the same patients the BLN Assay performance versus the 
performance of histologic intraoperative tests. Not all clinical sites used histologic 
intraoperative tests. All tests are compared with OHR. The assay detected about 
10% more metastases than did frozen section (86 assay positive versus 77 
frozen section positive of 90 OHR positive) and nearly 30% more than did touch 
preparation (7 assay positive versus 5 touch prep positive of 11 OHR positive).  
Early-stage disease and lobular cancers can be difficult cases in which to 
accurately detect metastases. Table 5 shows the performance of the BLN Assay 
versus that of frozen section in early-stage disease and in patients with lobular 
cancer. Data are shown for the validation study, cutoff study, and for both studies 
combined. The assay identifies metastatic disease in approximately 10% more 
patients with stage I disease and 25% more patients with lobular cancer than 
does frozen section (compared with total OHR positive).  
Permanent section histologic evaluations are reported to miss at least 10% to 
15% of metastases >.2 mm because of practical limitations in sampling [7] and 
[12]. The same sampling errors necessarily contribute to the lack of perfect 
agreement between the BLN Assay and the OHR. This sampling error would be 
expected to be most apparent when metastases are small and infrequent, as with 
micrometastases. Figure 1 shows that the assay agreement with positive OHR 
found on adjacent ~2-mm node slabs is best when the metastases are larger and 
likely to be distributed across the assay and histology node pieces (the P value of 
Cochran-Armitage test for trend is <.001).  
There are fewer cases of BLN Assay–positive/histology-negative results when 
histologic sampling accuracy is increased. Thus, assay positivity is better 
matched by histology when more extensive sampling is used for the histologic 
evaluation (central and site slides combined) because this reduces the number of 
metastases being missed by histology (Table 6).  
Sampling errors in histology testing are apparent when comparing histologic 
evaluations on the 2 sets of histologic slides: site slides versus central slides. 
These are nearby sections from the same ~2-mm node slabs, yet significant 
disagreements are seen where 1 set of slides contain metastatic tissue and the 
other set does not (Table 7, Table 8 and Table 9). The lack of perfect agreement 
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is caused by the analysis of different section samples from the same lymph node 
because significant metastases can be missed in nearby tissue left uncut on the 
block [13] and [14]. If site slide findings are compared with central slide findings 
as the reference, the agreement of the 2 histologic evaluations approximates the 
agreement between the BLN Assay and OHR on different ~2-mm node slabs. 
These data confirm that the lack of perfect agreement between OHR and the 
BLN Assay is primarily caused by the evaluation of different parts of the node.  
 
Comments 
The currently recommended protocol for SLN processing (according to the 
College of American Pathologists, 5 µm from 3 levels of each 2- to 3-mm 
fragment of the node [15]), guarantees evaluation of <1% of the volume of the 
selected tissue [16]. Comprehensive histologic examination of a 1.5-cm lymph 
node aimed at finding any metastasis ≥.2 mm would require 75 sections, which is 
unobtainable in common practice. This limitation in the current standard of care 
makes it challenging to evaluate newer tests that are able to sample more tissue 
and are likely to be more sensitive than the “gold standard” reference test. The 
current study evaluated a new molecular test against a permanent section 
histologic protocol that was more thorough than is usually performed and used a 
central review of histologic slides to reduce evaluation errors. The study also 
evaluated histologic results on 2 sets of tissue sections taken from nearby 
regions of the same node. By comparing site slide findings to central slide 
findings, an estimate of sampling errors (differences caused by testing of 
different tissue from the same node) can be made. Because the BLN Assay 
produces a result by testing fresh homogenized tissue, the same tissue cannot 
be tested by both the assay and permanent section histology, which requires 
fixed tissue. This sampling difference will necessarily lead to disagreements 
between the assay and histology, especially when metastases are smaller and 
less widely distributed in the node.  
The BLN Assay is a molecular test that can test 50% or more of the node in time 
to permit intraoperative evaluation. In a prospective study of 416 patients, with 
fresh nodal tissue tested by 11 clinical sites, the assay yielded efficient 
intraoperative detection of clinically important sentinel node metastasis, which 
will allow the surgeon and the patient to avoid a second operation for completion 
axillary dissection in 98% of patients if the policy is to return for metastases >2 
mm or 88% if the policy is to return for any metastasis >.2 mm. Micrometastases 
(from .2 to 2.0 mm) were less frequently detected (57%) and assay-negative 
results in nodes found positive by histology were rare (4%).  
The disagreements seen between permanent section histology performed on 
adjacent-node slabs and the BLN Assay results were very similar to the 
disagreements seen between histology preformed on site slides versus central 
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slides. These data indicate that when the assay and histology disagree, both 
tests are likely to be correct for the tissue portions each is evaluating. 
Discrepancies between evaluations on different node tissue (whether assay 
versus histology or histology versus histology) are greatest when metastases are 
small because they are poorly distributed in the node tissue. These findings 
support the need for tests that can efficiently evaluate more of the node for 
clinically significant metastases because breast cancer is found earlier and 
earlier and metastases will more likely be smaller.  
As reported previously [17], in cases for which the BLN Assay result and the 
OHR were different, residual node homogenate or RNA extract from the assay 
testing was evaluated with other molecular markers for nodal metastases 
including B305D, B726, prolactin inducible protein, and prostate-derived Ets 
transcription factor [18], [19] and [20]. This testing was performed to confirm the 
BLN Assay results on the same tissue. These independent molecular test results 
confirmed as positive 76% of the BLN Assay–positive/OHR-negative nodes and 
confirmed as negative 100% of the BLN Assay–negative/OHR-positive nodes. 
These findings again suggest that when the BLN Assay and OHR are in 
disagreement, both are correct for the nodal portions each is evaluating.  
Four percent of patients (17/416) had BLN Assay–positive results with no 
metastasis detected by conventional histology in adjacent tissue slabs. Could the 
assay produce real false-positive findings and lead to unnecessary axillary 
dissections? For reasons supported by our findings, we conclude that the BLN-
positive/OHR-negative cases represent misses of metastatic disease by 
conventional histology. Histologic assessment of study sections taken 
immediately adjacent to standard site sections used for patient care shows the 
same study negative/standard-section positive rate. Study and standard site 
slides were all reviewed by the same pathologists. The assay is calibrated in in 
vitro studies to require approximately 2,000 cells to yield a positive result. 
External controls act as a further safety net against truly false-positive results. 
Recalibrating the assay cutoff to ignore or miss significant disease, at precisely 
the rate it is missed by conventional histology, would necessarily lead to lower 
sensitivity for the detection of clinically significant disease.  
More detailed evaluation of the BLN Assay results indicates that the assay may 
be particularly helpful for difficult-to-detect early-stage breast cancer metastases 
or metastases from lobular cancer. Compared with current histologic frozen 
section intraoperative testing, the BLN Assay showed improved sensitivity 
ranging from approximately 10% to 30%. Another advantage of the BLN Assay 
over frozen sectioning is that more tissue can be evaluated efficiently and there 
is no freezing artifact on the portions of node undergoing permanent section 
histology.  
In summary, these data support the use of the BLN Assay as a properly 
calibrated intraoperative molecular test that can reduce the need for second 
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surgeries to complete the axillary dissection on SLN-positive patients. In addition, 
the assay has value in augmenting permanent section histologic results to obtain 
better certainty of a correct node diagnosis by evaluating more of the tissue. The 
pathologist, surgeon, and patient can be more certain a negative node diagnosis 
is accurate when both the BLN Assay result on half of the node and standard 
histology on the other half are negative.  
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TABLES & FIGURES 
 
Table 1.  
Summary of BLN Assay results and OHR agreement  
Assay−/OHR− Assay+/OHR+ Assay+/OHR− Assay−/OHR+ N % Agreement 
278 (67%) 106 (25%) 17 (4%) 15 (4%) 416 92.3 
For OHR, + is metastases >.2 mm and − is metastases ≤.2 or no detectable metastases. 
 
Table 2.  
Assay performance by stage and type of breast cancer  
Tumor 
stage/type N Assay−/OHR− Assay+/OHR+ Assay+/OHR− Assay−/OHR+ 
% 
Agreement 
Stage I 247 202 (82%) 29 (12%) 10 (4%) 6 (2%) 93.5 
Stage II 125 54 (43%) 55 (44%) 7 (6%) 9 (7%) 87.2 
Stage III 20 8 (40%) 12 (60%) 0 (0%) 0 (0%) 100 
Invasive 
ductal 335 223 (67%) 87 (26%) 14 (4%) 11 (3%) 92.5 
Invasive 
lobular 57 34 (60%) 16 (28%) 3 (5%) 4 (7%) 87.7 
Invasive 
other 23 20 (87%) 3 (13%) 0 (0%) 0 (0%) 100 
 
 
Table 3.  
BLN assay results and OHR agreement in patients with lobular cancer  
Study N Assay−/OHR− Assay+/OHR+ Assay+/OHR− Assay−/OHR+ % Agreement 
Validation 57 34 (60%) 16 (28%) 3 (5%) 4 (7%) 87.7 
Cutoff 40 26 (65%) 10 (25%) 1 (3%) 3 (8%) 90.0 
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Study N Assay−/OHR− Assay+/OHR+ Assay+/OHR− Assay−/OHR+ % Agreement 
Combined 97 60 (62%) 26 (27%) 4 (4%) 7 (7%) 88.7 
 
Table 4.  
Assay versus other intraoperative test performance  
N Test method Test−/OHR− Test+/OHR+ Test+/OHR− Test−/OHR+ % Agreement 
319 Frozen Section 224 (70%) 77 (24%) 5 (2%) 13 (4%) 94.4 
 Assay 216 (68%) 86 (27%) 13 (4%) 4 (1%) 94.7 
29 Touch Prep 18 (62%) 5 (17%) 0 (0%) 6 (21%) 79.3 
 Assay 18 (62%) 7 (24%) 0 (0%) 4 (14%) 86.2 
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Table 5.  
Assay and frozen section performance in stage I and lobular cancer patients  
Study N Test method Test−/OHR− Test+/OHR+ Test+/OHR− Test−/OHR+ % Agreement 
Validation study        
 Stage I 187 Frozen 158 (84%) 22 (12%) 3 (2%) 4 (2%) 96.3 
 Assay 155 (83%) 25 (13%) 6 (3%) 1 (1%) 96.3 
 Lobular 45 Frozen 30 (67%) 9 (20%) 1 (2%) 5 (11%) 86.6 
  Assay 29 (64%) 14 (31%) 2 (4%) 0 (0%) 95.6 
Cutoff study        
 Stage I 100 Frozen 82 (82%) 11 (11%) 1 (1%) 6 (6%) 93.0 
  Assay 77 (77%) 12 (12%) 6 (6%) 5 (5%) 89.0 
 Lobular 24 Frozen 15 (63%) 6 (25%) 0 (0%) 3 (12%) 87.5 
  Assay 15 (63%) 7 (29%) 0 (0%) 2 (8%) 91.7 
Combined studies        
 Stage I 287 Frozen 240 (84%) 33 (11%) 4 (1%) 10 (4%) 95.1 
  Assay 232 (81%) 37 (13%) 12 (4%) 6 (2%) 93.7 
 Lobular 69 Frozen 45 (65%) 15 (22%) 1 (1%) 8 (12%) 86.9 
  Assay 44 (64%) 21(30%) 2 (3%) 2 (3%) 94.2 
_______________________ 
Authors’ version prior to publication.  The published version is available at 
http://dx.doi.org/10.1016/j.amjsurg.2007.07.008, copyright © 2007 by Excerpta Medica Inc. 
Table 6.  
Assay performance by extent of histologic analysis  
Reference 
histology N BLN−/Hist− BLN+/Hist+ BLN+/Hist− BLN−/Hist+ 
% 
Agreement 
Central slides 
only 407 278 (68%) 91 (22%) 27 (7%) 11 (3%) 90.7 
Site slides only 407 275 (68%) 95 (23%) 23 (6%) 14 (3%) 90.9 
Central & site 
slides 407 275 (68%) 101 (25%) 17 (4%) 14 (3%) 92.4 
 
Table 7.  
Agreement between site slide results and central slide results  
Site slides Central slides 
 >2 mm .2–2 mm <.2 mm None detected Total 
>2 mm 79 3 0 4 86 
.2–2 mm 5 9 0 9 23 
<0.2 mm 0 2 0 4 6 
None detected 3 1 1 288 293 
Total 87 15 1 305 408 
 
 
 
Table 8.  
Summary of site slides and central slides agreement  
Site−/central− Site+/central+ Site+/central− Site−/central+ N % Agreement 
293 (72%) 95 (23%) 13 (3%) 6 (2%) 408 95 
+ is metastases >.2 mm and − is metastases ≤.2 or no detectable metastases. 
 
 
_______________________ 
Authors’ version prior to publication.  The published version is available at 
http://dx.doi.org/10.1016/j.amjsurg.2007.07.008, copyright © 2007 by Excerpta Medica Inc. 
 
Table 9.  
Site slides and central slides agreement for patients with detectable nodal tumor 
cells  
Site and/or central N Site+/central+ Site+/central− Site−/central+ Total disagree 
>2 mm 94 87 (93%) 4 3 7 (7%) 
.2–2 29 17 (59%) 9 3 12 (41%) 
<0.2 7 2 (29%) 4 1 5 (71%) 
 
 
 
Fig. 1.  
BLN assay positivity by the size of metastases in the adjacent tissue.  
 
 
